BioCryst to Report Third Quarter 2025 Financial Results on November 3
BioCryst (Nasdaq: BCRX) will report third quarter 2025 financial results on Monday, November 3, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCryst (Nasdaq: BCRX) will report third quarter 2025 financial results on Monday, November 3, 2025. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
Dial-in numbers are 1-844-481-2942 (U.S.) and 1-412-317-1866 (international). A live webcast and replay will be available in the investors section of the company website at www.biocryst.com.
Details
News Market Reaction – BCRX
On Oct 20, the day this news came out, BCRX closed 4.52% above the previous close.
Data tracked by StockTitan Argus for the Oct 20 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.